Assay Detail
Functional
CHEMBL5538345
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiproliferative activity against human DOHH-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
5
Total Activities
5
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Homo sapiens |
| Cell Type | DOHH-2 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Publication
Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 5 | 5.60 | 6.24 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL98 | VORINOSTAT | 4.0 | 1 | 6.24 |
| CHEMBL2017974 | BUPARLISIB | 3.0 | 1 | 5.85 |
| CHEMBL4087968 | — | — | 1 | 5.37 |
| CHEMBL5592140 | — | — | 1 | 5.28 |
| CHEMBL5569425 | — | — | 1 | 5.27 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL98 | VORINOSTAT | IC50 | = | 580.0 | nM | 6.24 |
| CHEMBL2017974 | BUPARLISIB | IC50 | = | 1400.0 | nM | 5.85 |
| CHEMBL4087968 | — | IC50 | = | 4300.0 | nM | 5.37 |
| CHEMBL5592140 | — | IC50 | = | 5300.0 | nM | 5.28 |
| CHEMBL5569425 | — | IC50 | = | 5400.0 | nM | 5.27 |